- Home
- EXEL
EXEL
Exelixis Inc.
as of 12-05-2025 3:44pm EST
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
| Founded: | 1994 | Country: | United States |
| Employees: | N/A | City: | ALAMEDA |
| Market Cap: | 11.1B | IPO Year: | 2000 |
| Target Price: | $44.73 | AVG Volume (30 days): | 2.5M |
| Analyst Decision: | Buy | Number of Analysts: | 24 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 2.38 | EPS Growth: | 53.55 |
| 52 Week Low/High: | $31.90 - $49.62 | Next Earning Date: | 11-04-2025 |
| Revenue: | $2,288,218,000 | Revenue Growth: | 9.93% |
| Revenue Growth (this year): | 9.14% | Revenue Growth (next year): | 12.51% |
AI-Powered EXEL Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Exelixis Inc. (EXEL)
Director
Avg Cost/Share
$43.12
Shares
27,532
Total Value
$1,187,234.90
Owned After
1,553,262
SEC Form 4
EVP, Commercial
Avg Cost/Share
$42.58
Shares
28,043
Total Value
$1,194,070.94
Owned After
374,029
SEC Form 4
EVP, Commercial
Avg Cost/Share
$41.94
Shares
44,187
Total Value
$1,852,857.23
Owned After
374,029
Director
Avg Cost/Share
$43.55
Shares
100,000
Total Value
$4,355,000.00
Owned After
1,189,228
SEC Form 4
Director
Avg Cost/Share
$41.97
Shares
24,622
Total Value
$1,032,413.72
Owned After
21,380
EVP, Research and Development
Avg Cost/Share
$42.50
Shares
48,383
Total Value
$2,056,277.50
Owned After
664,778
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| JOHNSON DAVID EDWARD | EXEL | Director | Nov 25, 2025 | Buy | $43.12 | 27,532 | $1,187,234.90 | 1,553,262 | |
| Haley Patrick J. | EXEL | EVP, Commercial | Nov 21, 2025 | Sell | $42.58 | 28,043 | $1,194,070.94 | 374,029 | |
| Haley Patrick J. | EXEL | EVP, Commercial | Nov 20, 2025 | Sell | $41.94 | 44,187 | $1,852,857.23 | 374,029 | |
| PAPADOPOULOS STELIOS | EXEL | Director | Nov 12, 2025 | Sell | $43.55 | 100,000 | $4,355,000.00 | 1,189,228 | |
| Beckerle Mary C | EXEL | Director | Nov 11, 2025 | Sell | $41.97 | 24,622 | $1,032,413.72 | 21,380 | |
| Aftab Dana | EXEL | EVP, Research and Development | Nov 11, 2025 | Sell | $42.50 | 48,383 | $2,056,277.50 | 664,778 |
Compare EXEL vs Leading Stocks
See how EXEL stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "EXEL Exelixis Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.